iBIO Welcomes New Members and Board Members


The iBIO Community Continues to grow.

iBIO would like to welcome the following new members.

CarboSynUSA – a privately held biotechnology company specializing in the synthesis, analysis and manufacture of carbohydrates and nucleosides.

Luminex – We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety.

Protide Pharma – a fully integrated organization devoted to the discovery, development and commercialization of technologies and processes in clinical cell therapy, regenerative medicine, transfusion medicine, cell engineering, and transplantation.

iBIO is also proud to announce three new members to our board of directors:

Drue Duncan, Director, US Public Affairs & State Government Relations, Pfizer

Blair Komasinski, Assurance Partner, Ernst & Young

Salim Mujais, Senior Vice President, Therapeutic Area Head, Astellas Pharma

Share This Post:

Comments are closed.